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Abstract: 
Additive manufacturing (AM) techniques have gained interest in the tissue engineering field thanks 
to their versatility and unique possibilities of producing constructs with complex macroscopic 
geometries and defined patterns. Recently, composite materials — namely heterogeneous 
biomaterials identified as continuous phase (matrix) and reinforcement (filler) — have been proposed 
as inks that can be processed by AM to obtain scaffolds with improved biomimetic and bioactive 
properties. Significant efforts have been dedicated to hydroxyapatite (HA)-reinforced composites, 
especially targeting bone tissue engineering, thanks to the chemical similarities of HA with respect 
to mineral components of native mineralized tissues. Here we review applications of AM techniques 
to process HA-reinforced composites and biocomposites for the production of scaffolds with 
biological matrices, including cellular tissues. The primary outcomes of recent investigations in terms 
of morphological, structural, and in vitro and in vivo biological properties of the materials are 
discussed. We classify the approaches based on the nature of the matrices employed to embed the HA 
reinforcements and produce the tissue substitutes and report a critical discussion on the presented 
state of the art as well as the future perspectives, to offer a comprehensive picture of the strategies 
investigated as well as challenges in this emerging field. 
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LIST OF ABBREVIATIONS 
3D Three-dimensional 
ALP Alkaline Phosphate 
AM Additive Manufacturing 
BMP-7 Bone Morphogenetic Protein 7 
BMSC Bone Marrow-derived Stem Cells 
BSP Bone Sialoprotein 
C3H Mouse Embryo Cell 
CH Chitosan 
COL1 Collagen I antibody 
CS Compressive Strength 
CT Computed Tomography 
DGEA Asp-Gly-Glu-Ala 
DIW Direct Ink Writing 
E Young Modulus 
ECM ExtraCellular Matrix 
EDC 
1-ethyl-3-3-dimethylaminopropylcarbodiimide 
hydrochloride 
FDM Fused Deposition Modeling 
G’ Shear Storage Modulus 
G’’ Shear Loss Modulus 
HA Hydroxyapatite 
HACC Quaternized Chitosan 
hASC human Adipose-Derived Stem Cell 
hBMSC human Bone Marrow Stem Cells 
HMWPE High Molecular Weight Polyethylene 
hMSC human Mesenchymal Stem Cell 
h-OB human Osteoblasts  
LAP Laser Assisted Printing 
LMWPE Low Molecular Weight Polyethylene 
MC3T3-E1 
Osteoblast Precursor Cell Line derived from Mus 
Musculus 
MD Molecular Dynamics 
MG-63 Osteosarcoma cell 
MPP Mitochondrial Processing Peptidase 
MSC Mesenchymal Stem Cell 
OCN Osteocalcin 
OPN Osteopontin Gene 
PA Polyamide 
PCL Polycaprolactone 
PE Polyethylene 
PEEK 
Poly(ether-ether-ketone) or Poly(oxy-1,4-
phenylene-oxy-1,4-phenylenecarbonyl-1,4-
phenylene) 
PGA Phosphoglyceric Acid 
PLA Polylactide 
PLGA Poly(lactic-co-glycolic acid) 
PLLA Poly (L-lactic acid) 
PMMA Poly(methyl methacrylate) 
PVA Poly(vinyl alcohol) 
RGD Arg-Gly-Asp 
SA Sodium Alginate 
SDF1 Stromal cell-Derived Factor 1 
SEM Scanning Electron Microscope 
SFF Solid Free Form 
SL Stereolithography 
SLS Selective Laser Sintering 
SrHA Strontium-HA 
ST-2 
Clonal stromal cell line from bone marrow of 
BC8 mice 
T Temperature 
TCP Tricalcium Phosphate 
TE Tissue Engineering 
Tg Glass Transition Temperature 
TNF Tumor Necrosis Factor 
Tsol-gel Sol-Gel Temperature 
UHMWPE Ultra-High Molecular Weight Polyethylene 
UV Ultra Violet 
η* Complex Viscosity 
MPP Mitochondrial Processing Peptidase 
  
  5 
Introduction 
Since 1984, when Prof. Charles Hull showed one of its first uses at the Massachusetts Institute of 
Technology, Additive Manufacturing (AM) has been widely employed in many fields, such as the 
arts, food industry, manufacturing, and design. However, AM found a remarkable framework in 1993, 
when a team of researchers published a study concerning its employment within the biomaterials and 
Tissue Engineering (TE) field.[1] These researchers explored for the first time the capabilities of this 
technique in the TE field as a means to repair tissue defects and damaged organs.[2] This underlying 
idea consisted of creating resorbable 3D-structures, referred as scaffolds, to regenerate tissues. AM, 
as largely demonstrated, has allowed scaffolds to be tailored in terms of specific features such as 
shape, micro/macro porosity, and pore interconnectivity ratio while, at the same time, the fabrication 
time was significantly reduced.[3] Since then, AM has spread into a wide family of techniques to 
fabricate customized and complex three-dimensional (3D) constructs, being a much more versatile 
alternative to other traditional approaches where complex topologies are difficult to achieve (e.g., 
electrospinning [4], machining[5] or screw extrusion).[6] These 3D scaffolds have then been extensively 
explored as supports for cell attachment, growth and differentiation, aiming at forming new 
extracellular matrix,[7,8] promoting in vivo tissue regeneration or fabricating in vitro tissue models. 
Despite a number of mere materials can be processed by AM to obtain scaffolds, an increasing interest 
has been focused on processing composites, multiphase materials able to maximize the properties of 
the single components, when taken alone.[9] Composites for TE are usually composed of a matrix, a 
reinforced part (i.e., particles, fibrils and flakes) and, possibly, cellular tissues. Composites used for 
AM purposes (i.e., biomaterial inks or bioinks)[10] can be classified in two groups: hard and soft 
materials, depending on the matrix used for each specific application.[11–14] The first class includes 
materials with matrices possessing mechanical properties that assure stability after the printing (e.g., 
metals, ceramics, and many thermoplastic polymers). However, due to the procedures needed for 
processing such materials, it has been shown that cells must be seeded at completed fabrication 
process of the scaffold to assure a sufficient biological viability. As for the second class, soft matrices 
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are typically hydrogels, hydrophilic polymers able to hold a large amount of water (from 10 - 20% to 
thousands of times their dry weight)[15] while assuring structural integrity when adequately 
processed,[16,17] and allowing permeability to nutrients to promote new tissue formation.[18–20] Figure 
1 summarizes the different matrices employed to fabricate HA-reinforced composites that will be 
reviewed in this paper. 
 
Figure 1. (a) Hard and (b) soft HA-reinforced matrices fabricated via additive manufacturing for 
tissue engineering. 
Besides their hard/soft nature, there are specific features that each material must comply with in order 
to be a good candidate for the fabrication of scaffolds by AM. Firstly, biomaterial inks must possess 
rheological properties that allow their processability. Since this feature plays a dominant role in the 
selection of the AM technique, several studies have been published to find the optimized rheological 
features for specific material classes (e.g., viscosity, extensional viscosity, surface tension depending 
on the printing technique).[21] Furthermore, the mechanical properties must be suitable for the targeted 
application (e.g., bone reconstruction);[22] this issue is particularly relevant for soft biocomposites 
where a crosslinking process is often pursued to overcome this concern. The last structural property 
to be taken into account is the capability of the scaffold in furnishing an adequate porosity: although 
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several authors have achieved good results in making unidirectional porosities,[23] a multidirectional 
scenario (i.e., interconnections between pores) may help over a more homogenous tissue infiltration 
and vascularization, features that prevent necrosis and rejections in implant sites.[24] 
From a biological point of view, the composites must be a non-toxic environment for efficient cell 
seeding, proliferation, and differentiation, possibly granting progressive in situ integration within the 
host tissue. As exhaustively detailed in the following sections, this property is significantly connected 
to the AM techniques employed to process the composites.  
The aim of this paper is to review the advancements for HA-reinforced materials by proposing a 
classification based on the employed matrices (i.e., hard and soft) in the framework of the AM 
techniques. Finally, a critical discussion on current and future challenges in the field is treated. 
Additive manufacturing techniques for HA and HA-reinforced composites 
Tissue regeneration by HA-reinforced tissue-engineered scaffolds processed by AM requires three 
fundamental steps: (1) identification of the missing/damaged tissue and generation of its digital 
topology (Figure 2A), (2) production of the composite and fabrication of the scaffold/substitute via 
AM (Figure 2B), and (3) replacement of the native tissues (Figure 2C). Besides, the fabrication step 
is crucial, and it plays a crucial role in the process, critically affecting the final outcome of the tissue 
regeneration. 
According to the American Chemical Society, it is possible to roughly classify AM methods for tissue 
engineering in three main categories: extrusion-based, laser-based and droplet-based techniques.[25] 
Due to the high viscosity of the HA-reinforced materials given by the addition of the ceramic 
component, droplet-based techniques cannot be employed since they are compatible only with low 
viscosities (< 10 mPa·s) and high shear rates (105 – 106 s-1).[26–31] In contrast, HA-reinforced 
composites have been successfully fabricated by extrusion-/laser-based processes (Figure 2B). 
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Figure 2. Additive manufacturing techniques used for the fabrication of hydroxyapatite-reinforced 
composites as scaffolds for tissue engineering applications. From (A) the generation of the digital 
topology of the damaged/missing tissue to (B) the fabrication of the scaffold through AM approaches 
with a HA-based bioink and (C) the final tissue regeneration. 
For extrusion-based processes, including Direct Ink Writing (DIW, also called Robocasting) and 
Fused Deposition Modeling (FDM), the raw material is ejected by a nozzle, namely an extruder, 
steered through a mechanical or electromagnetic actuator. While in FDM the material, usually 
synthetic thermoplastics, is printed at high temperatures (140 – 250 °C) at melt state to reduce the 
viscosity,[32] DIW allows the extrusion at low temperatures (e.g., room temperature).[12] This specific 
advantage of DIW makes it suitable also to print cells without affecting their viability, not possible 
when using FDM. 
Laser-Based techniques include Stereolithography (SL), Selective Laser Sintering (SLS) and Laser 
Assisted Printing (LAP). SL is the oldest approach and consists of the projection of a direct-light (i.e., 
Ultra Violet (UV), laser) on a viscous photosensitive polymer solution to crosslink it and, thus, 
promote its solidification. Alternatively, with SLS, a laser beam is focused on the material, in the 
shape of powder, to selectively sinter it.[33] From a biological point of view, SLS is unsuitable for cell 
encapsulation due to the high energy density employed to make the construct; contrary to SLS, under 
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certain conditions, SL assures high cell viability.[34–36] Finally, in LAP, a laser (spot size = 40 – 100 
μm) is concentrated on a donor layer that buffers the energy supply to the biomaterial ink, eventually 
deposited on a receiver surface in the shape of droplets. The interposition of an absorbent thick layer 
also allows the direct printing of living tissues (i.e., cells) without significantly affecting their 
viability.[37–39] 
A different approach, often referred to as indirect AM, is represented by the Solid Free Form 
technique (SFF). Historically, the SFF term has been associated as a synonym of AM, hence it a 
family of techniques that aims at fabricating structures with a layer-by-layer approach from an image-
based/3D topology.[40] In this review, however, the term SFF will be referred to the cases in which 
AM is used to create molds in which to cast a slurry of material to be eventually treated (e.g., 
dehydration) to enhance the crosslinking and tune pore interconnectivity.[41] The evident simplicity 
of the approach is, at the same time, its main drawback since the topology of the shapes intrinsically 
sets the constraints on the design of the constructs. 
Hydroxyapatite 
HA is a ceramic material with a hexagonal crystallographic structure, chemically described by the 
Ca10(PO4)6(OH)2 formula (Figure 3). Its successful employment in TE is due to its chemical structure, 
similar to the mineralized constituents of bone. Although native tissues do not contain neat HA since 
they possess other impurities (e.g., carbon, hydrogen phosphate, etc.), HA has been commonly used 
for bone regeneration purposes[41–44] due to its excellent physicochemical properties such as 
osteoconductivity, bioactivity, resorbability and slow-decaying properties.[45–48] One of the most 
interesting features of HA concerns the cell response modification based on its dimensions: 
nanometer sizes increase intracellular uptake and reduce cell viability in vitro. [49] Moreover, size and 
crystallinity of HA particles may affect stability and inflammatory response, increased if the 
dimensions are smaller than 1 μm.[50] 
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Also from a mechanical point of view, HA shows interesting features in terms of stiffness (Young 
Modulus E = 35 – 120 GPa) and compressive strength (CS) (120 – 900 MPa)[51] and toughness 
investigated by a number of molecular dynamics (MD) models and confirmed experimentally.[52–54] 
For instance, microspheres of HA have been studied by many research teams for bioengineering 
applications due to their potential as local drug and protein delivery systems.[50,55,64,65,56–63] On the 
other hand, few studies have investigated the incorporation of HA microspheres within polymeric 
matrices produced via AM.[65,66] 
 
Figure 3. Hexagonal crystallographic structure of the hydroxyapatite crystal. 
Researchers have been fabricating neat HA structures by means of different AM techniques building 
osteoconductive scaffolds with tuned microstructures with pores ranging from 100 to 1200 μm,[67–69] 
able to successfully support the formation of new vascularized tissues.[70] Different approaches have 
been pursued: SL,[71] LAP,[72] SFF,[68,69,73] SLS [67] and DIW.[47,74,75] Whereas with laser-based 
techniques it was possible to obtain structures that, tested both in vitro and in vivo in rodent or canine 
models, demonstrated good adhesion, proliferation, and osteochondral differentiation of the seeded 
human Mesenchymal Stem Cells (hMSCs) and absence of inflammation,[67,71,72] it is with SFF and 
DIW that the best results were achieved. 
SFF is the simplest method involving AM only for preparing molds in which to cast a slurry of 
material composed of HA powder mixed with demineralized water and chemicals. Despite its 
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intrinsic simplicity, it was possible to get stratified structures – layer thickness in the order of 0.05 
mm with higher porosity (i.e., up to 44%) in contrast to DIW (i.e., up to 37%).[69,73] 
DIW of HA is generally hard to perform without intermediate steps aimed at treating raw materials 
characterized by low crystal growth rates (i.e., 2.7 x 10-7 mol Ca10(PO4)6(OH)2 min
-1·m-2).[74,75] Thus, 
Leukers et al. fabricated scaffolds made of spray-dried HA-granulate with polymeric additives to 
improve bonding and flowability and a polymer blend (Schelofix) as binder. In order to improve 
structural strength, a further sintering was performed at 1300 °C for 2 h revealing, eventually, how 
the seeded cells grew especially among the granules.[47] 
Miranda et al. employed DIW with a 250 μm nozzle to deposit HA filaments at 20 mm∙s-1. After 
printing, the constructs were dried at 400 °C for 1 h to allow the evaporation of the organics, achieving 
a porosity close to 40% with Young Modulus equal to 7 ± 2 GPa.[76] Furthermore, Carrel et al. 
prepared stratified HA and tricalcium phosphate (TCP) scaffolds to evaluate bone regeneration in 
sheep calvarian model. Compared to standard granular substitutes, HA structures showed higher 
osteoconductivity properties. 
As discussed above, 3D printed HA scaffolds have been widely employed in tissue engineering to 
regenerate/substitute bone tissue (Table 1). Due to its intrinsic stability and shapeability, HA-based 
scaffolds have been successfully fabricated with all the previously listed AM techniques, with the 
only exception represented by the droplet-based technique, probably due to intrinsic high viscosity 
that may induce clots in the cartridges. Scaffolds with tunable pore size (300 - 1250 μm) for hosting 
viable cells were successfully fabricated. As reported in Table 1, biological in vitro assessments 
demonstrated how HA-based constructs are able to promote cell proliferation and differentiation. 
Moreover, a few number of in vivo tests on animals have shown how implants might induced mild 
inflammation reactions close to the implantation sites that, however, were completely resorbed in less 
than one month.[72] 
Despite the successful validation of pure HA-based scaffolds, this ceramic component has also gained 
interest as reinforcement for composites processed via AM. 
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Table 1. Literature review of HA constructs processed by additive manufacturing technologies. 
AM 
method 
Porosity [%]/ 
Pore size [µm] 
Structural 
properties 
Cell type Cellular response Reference 
SL 
79.6% / 1250 µm - 69.3% / 
790 µm - 48.2% / 500 µm 
- hMSC 
Cell proliferation, 
and osteochondral 
differentiation 
[71] 
LAP - - 
None – In vivo laser 
printing 
Inflammation that 
was completely 
resorbed after 21 
days 
[72] 
SFF 44% - 300 µm  
Clonal stromal cell 
line from bone 
marrow of BC8 
mice (ST-2) 
Cell proliferation and 
differentiation 
[69] 
SFF 400 - 1200 µm  - - [68] 
SFF 52% / 286 - 376 µm  
Goat Bone marrow-
derived stem cells 
(BMSC) 
Cell proliferation and 
ectopic bone 
formation 
[73] 
SLS - 
Bending strength: 
66.2 MPa 
- - [67] 
DIW 42% CS = 27 MPa - - [75] 
DIW 500 µm - 
Osteoblast 
Precursor Cell Line 
derived from Mus 
musculus 
(MC3T3-E1) 
Cell proliferation and 
growth 
[47] 
DIW - - 
human osteoblast 
cells (h-OB) 
Cell spreading, 
adhesion and 
differentiation 
[74] 
Hydroxyapatite-reinforced biocomposites via additive manufacturing 
A possible classification for composites is based on the matrix used for the constructs. In the specific 
case of the HA-reinforced biomaterials, only few materials have been processed via AM (Table 2).  
Table 2. Literature review of hydroxyapatite-reinforced composites processed by additive 
manufacturing technologies for the production of scaffolds. 
AM techniques EB SLS SFF 
C
o
m
p
o
si
te
s 
H
a
rd
 
M
a
tr
ic
e
s 
Polylactide 
(PLA) 
[77–79] - [66] 
Polycaprolactone 
(PCL) 
[77,80–83] [84,85] - 
Poly(ether-ether-
ketone) (PEEK) 
- [86] - 
Polyethylene 
(PE) 
- [87] - 
Polyamide (PA) [88] - [89] 
Poly(methyl 
methacrylate) 
(PMMA) 
- [90–92] - 
S
o
ft
 
M
a
t
ri
ce s Alginate [93–98] - - 
  13 
Collagen [99] - [100,101] 
Gelatin [102–105] - - 
Chitosan (CH) [106–111] - - 
Poly(vinyl 
alcohol) (PVA) 
- [112] - 
Silk [21,113] -  
The following two sections will present the main achievements over fabricating HA-reinforced 
composites via AM, based on the classification of the polymeric matrices (Figure 1). 
Hard matrix-based composites 
Hard matrices employed so far for HA-reinforced composites are synthetic polymers (e.g., PLA, 
PCL). Table 3 reports the main aspects for each study, detailed also in the following sections, focusing 
on the structural properties and biological responses. 
Table 3. Hard matrix-based hydroxyapatite reinforced composites: structural, morphological and 
biological properties. 
Material 
Pore size 
[µm]/ 
porosity 
[%] 
AM 
method 
Structural 
properties 
HA size/ 
distribution 
Cell 
type 
Cellular 
response 
Refere
nce 
P
L
A
 
55% DIW 
E in parallel to the 
printing plane: 
150 ± 40 MPa; 
E in perpendicular 
to the printing 
plane: 84 ± 9 MPa 
70 wt% - - [77] 
500 µm SFF CS = 1.46 MPa 
Average 
diameter 10 
μm 
CH/HA 50:50 
and CH/HA 
60:40 
MC3T3
-E1 
pre-
osteobl
astic 
cells 
Osteoblastic 
cells 
proliferation 
and 
differentiation 
[66] 
300 µm/ 
76% 
DIW 
CS = 30 MPa 
E = 1.9 GPa 
- 
hBMS
Cs 
Adhesion, 
proliferation 
and 
differentiation 
[78,79] 
P
C
L
 26% FDM 
CS = 15 MPa 
E = 80 MPa 
30 wt% HA 
MC3T3
-E1 
good cell 
biocompatibili
ty, and 
biodegradatio
n ability 
[81]. 
200 µm DIW - 20 wt% HA 
Grow 
factors: 
Bone 
regeneration 
[80] 
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Stromal 
cell-
derived 
factor 1 
(SDF1) 
and 
Bone 
morpho
genetic 
protein 
7 
(BMP7
) 
and 
periodontal 
integration 
500 µm DIW - 
0.03 µm / HA 
(4 mg):PCL 
(700 mg) 
Mesenc
hymal 
Stem 
Cell 
(MSCs) 
Excellent 
osteoconducti
ve and 
osteointegratio
n properties. 
High 
histocompatibi
lity 
[82] 
55% DIW 
E In parallel to 
the printing plane: 
110 ± 20 MPa 
E in perpendicular 
to the printing 
plane: 24 ± 5 MPa 
70 wt% - - [77] 
37% SLS 
E = 67 MPa 
CS = 3.2 MPa 
HA particles 
diameter 10 – 
100 µm 
BMP-7 
Tissue in-
growth 
[84] 
410 µm SLS 
E = 2.3 MPa 
CS = 0.6 MPa 
30% wt% of 
HA 
- - [85] 
- DIW 
CS = 7 MPa 
E = 40 MPa 
Strontium-
HA:PCL 
[0:100, 10:90, 
30:70, 50:50 
wt%] 
BMSCs 
Cell 
proliferation 
and osteogenic 
differentiation. 
Promotion of 
bone 
regeneration 
[83] 
P
E
E
K
 
- SLS - 
Powder 
Diameter 
below 60 μm/ 
10 – 40 wt% 
- - [86] 
P
E
 200 – 400 
µm 
SLS - 
HA 30% - 
40% wt% 
- - [87] 
P
A
 
300 – 500 
μm 
SFF 
CS = 117 MPa 
E = 5.6 GPa 
- - - [89] 
- DIW - - - - [88] 
P
M
M
A
 
40 -100 
µm / 30% 
SLS - 
50 g – 100 ml 
H3PO4 14 wt% 
PMMA 
- - [91,92] 
 
Polylactide (PLA) 
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Polylactide or polylactic acid (PLA) is among the most widely bioresorbable polymers approved by 
the U.S. Food and Drug Administration (FDA) for human clinical applications such as surgical 
sutures, cranio-maxillofacial augmentation, bone fixation, soft-tissue implants and implantable 
scaffolds.[114] It is a biocompatible polymer, synthesized by multiple ways (e.g., poly-condensation, 
ring-opening or enzymatic polymerization) from lactic acid monomers, which exist as two 
enantiomers, L- and D-lactic acid. This confers chiral property to PLA, for which it exists in different 
stereoisomers: poly(L-lactide) (PLLA), poly(D-lactide) (PDLA), and poly(DL-lactide) (PDLLA). 
The biocompatibility of this polymer makes it highly attractive for biomedical applications, in 
particular because its degradation products do not interfere with the healing process but, rather, they 
are metabolized through Kreb’s cycle and expelled. 
The chirality of monomer’s unit influence considerably its physico-chemical, mechanical and 
rheological properties, and consequently its degradation rate. In particular, by varying the 
enantiomeric units’ content, the PLA’s crystallinity may be controlled ranging from an 
amorphous/semi-crystalline to crystalline, increasing the mechanical feature of the polymer. Semi-
crystalline PLA has an approximate tensile modulus of 3 GPa, tensile strength of 50 – 70 MPa, 
flexural modulus of 5 GPa, flexural strength of 100 MPa, and an elongation at break of about 4%.[115] 
Also the molecular weight (MW) has a significant impact on the mechanical properties and 
degradation rate of the PLA. High MW PLA has a very high resorption time (2 - 8 years) that in vivo 
might lead to inflammation and infection.[116,117] Therefore, production of low MW PLA is desirable 
because it provides a shorter degradation rate, but at the same time it is able to guarantee suitable 
mechanical features for a period of time, which fit with bone fracture healing.[115] PLA with MW lower 
than 2000 Da behaves like a hydrogel, useful for drug delivery applications. From a mechanical point 
of view, it has been reported and increasing of the tensile modulus of PLLA of 2 time when the MW 
is raised from 50 to 100 kDa,[115,118] and tensile strengths of 15.5, 80 and 150 MPa, for varying the 
MW from 50 over 150 to 200 kDa, respectively.
[115,119] 
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Nevertheless, PLA processing parameters (such as injection or extrusion with or without an annealing 
step) affect the mechanical behavior of the polymer (Table 4). More specifically, a fast cooling after 
injection molding did not allow the polymer chains to rearrange into a crystalline structure; while 
after annealing, an important crystalline structure was recreated. PLA is also relatively hydrophobic, 
and this induces a lower cell affinity and lead to an inflammatory response from the living host upon 
direct contact with biological fluids. Moreover, also the lack of reactive side-chain groups makes 
PLA chemically inert, and consequently its surface and bulk modifications are among the main 
research topics.[115] 
Table 4. Mechanical properties (E, yield strength and elongation at break) of PLA processed by 
injection (PLA-I) and extrusion/injection (PLA-EI) without or with annealing (PLA-EIA).[115] 
Mechanical 
parameters 
PLA_I PLA_EI PLA_IA PLA_EIA 
E [GPa] 3.7 ± 0.1 3.9 ± 0.1 4.1 ± 0.1 4.1 ± 0.1 
Tensile strength 
[MPa] 
65.6 ± 1.3 65.2 ± 0.9 75.4 ± 0.9 77.0 ± 1.1 
Elongation at break 
[%] 
4.0 ± 0.8 5.4 ± 0.6 2.5 ± 0.2 3.3 ± 0.3 
PLA-based constructs reinforced with HA powder (diameter ranging 1 - 3 μm) were successfully 
printed via DIW by Russias et al., getting structures with acceptable porosity – about 55%. The ink 
was prepared by mixing 70 wt% of HA powder with PLA polymer and ethanol to tune the viscosity 
of the compound. The printing nozzle (diameter = 5 - 410 μm) ejected the slurry with a deposition 
speed ranging between 5 – 20 mm∙s-1: it was observed that lower speeds lead to clotting inside the 
nozzle whilst faster ones make the slurry discontinuous. Although no specific biological tests were 
performed, a mechanical assessment was carried out by evaluating the response of the constructs in 
parallel or perpendicularly to the printing plane, achieving results statistically comparable, but still 
far from the requirements needed to replace the bone: 150 ± 40 MPa and 84 ± 9 MPa in parallel and 
perpendicularly to the printing plane respectively (Figure 4).[77] Li et al. developed scaffolds by using 
SFF to fabricate a three-component scaffold with a woodpile structure consisting of PLLA, chitosan 
(CH) and HA microspheres at different ratios (60:40 and 50:50 CH/HA), with a macro-porosity of 
more than 50% together with micro-pores induced by lyophilization. The mechanical properties of 
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the PLLA/CH/HA composite scaffolds were compared with that of CH/HA 50:50 and CH/HA 60:40 
composites, obtaining 1.46, 1.31 and 1.07 MPa as compression modulus, respectively, which suggest 
the use of these scaffolds for non-load-bearing bone implants. 
 
Figure 4. Stress-strain curves from compression tests made on PLA/HA scaffolds (70 wt% HA) along 
the (a) perpendicular and (b) parallel directions with respect to the printing plane. The slopes, namely 
E, resulted equal to (a) 84 ± 9 MPa and (b) 150 ± 40 MPa. Lenses shows Scanning Electrode 
Microscope (SEM) micrographs after the mechanical test. Reprinted from [77] with permission – © 
2017 John Wiley and Sons. 
Comparing this with the data for human bone, the CS of the composite scaffold is still far from that 
of cortical bone (CS = 130 – 180 MPa, E = 12 – 18 x 103 MPa) and cancellous bone (CS = 4 – 12 
MPa, E = 0.1 – 0.5·103 MPa), but is closer to cartilage (strength of 4 – 59 MPa and modulus of 1.9 – 
14.4 MPa).[66,120] 
These scaffolds showed excellent biocompatibility and ability for three-dimensional tissue growth 
formed by MC3T3-E1 pre-osteoblastic cells. The pre-osteoblastic cells cultured on these scaffolds 
formed a network on the HA microspheres and proliferated not only in the macro-pore channels but 
also in the micro-pores themselves. The presence of PLLA in the composite scaffolds improved the 
initial cell proliferation and differentiation process up to 4 weeks, as revealed by the tissue growth 
and Alkaline Phosphate (ALP) enzyme activity. In the later stages, at 5 weeks, a decrease in ALP was 
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observed for PLLA composite scaffolds which might be due to a partial degradation of the 
polymer.[66] 
Later, to confer antimicrobial properties to the biomaterials, Yang et al. [78,121] used a quaternized 
chitosan (hydroxypropyltrimethylammonium chloride - HACC) grafted to a FDM-printed HA-
reinforced poly(lactic-co-glycolic acid) – PLGA - composite scaffold manufactured layer-by-layer 
(up to 24 layers).[121,122] Quaternized CH consists in the introduction of permanent positively charged 
quaternary ammonium groups to the polymer to enhance its water solubility and antibacterial feature 
over a broad pH range.[123] The 3D-printed HACC/PLGA/HA scaffolds showed a large homogeneous 
macro-porosity of about 76%, with an average pore size of about 300 µm and a highly interconnected 
micro-porosity, which could provide a suitable substrate for cell infiltration and bone ingrowth. The 
addition of HA induced an improvement of mechanical properties as demonstrated by the CS = 30 
MPa and E = 1.9 GPa, which appeared to be intermediate between mechanical properties of the 
cancellous and cortical bone.[124] These results demonstrated that this approach allowed to design and 
manufacture 3D-printed scaffolds as bone substitutes with mechanical properties reassembling 
closely those of bone tissues, which could be applied in vivo for cortical and cancellous bone 
repair.[121] The authors also proved that the use of quaternized chitosan decreased bacterial adhesion 
and biofilm formation under in vitro and in vivo conditions, disrupting microbial membranes and 
inhibiting the biofilm formation. In addition to the antibacterial activities of these 3D-printed 
scaffolds, attention was also paid to their biocompatibility and osteogenic activity. They 
demonstrated, in fact, that the incorporation of HA into the scaffolds significantly improved human 
Bone Marrow Stromal Cells (hBMSCs) adhesion, proliferation, spreading and the expressions of 
several critical osteogenic differentiation-related genes: early osteogenic markers Bone Sialoprotein 
(BSP) and Collagen I antibody (COL1), and relatively late markers Osteocalcin (OCN) and 
Osteopontin (OPN) genes. Furthermore, they also proved that HACC/PLGA/HA scaffold provided a 
satisfactory in vivo micro-environment for the neovascularization and tissue integration, which laid 
good foundation for the regeneration of bone defects in situ. 
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Polycaprolactone (PCL) 
Polycaprolactone (PCL) is an aliphatic thermoplastic polyester prepared by the ring-opening 
polymerization of the cyclic monomer ε-caprolactone,[125] which can proceed via anionic, cationic, 
coordination or radical polymerization mechanisms.[126] PCL is a hydrophobic, semi-crystalline 
polymer with a very low glass-transition temperature of (Tg = -60 °C); thus, it is commonly in the 
rubbery state with a high permeability under physiological conditions.[114] It is biodegradable but 
more stable compared to PLA because of its less frequent ester bonds per monomer; therefore, 
degradation takes longer, from several months to several years, for PCL chain fragments to be 
degraded in the body. This depends on its molecular weight, degree of crystallinity, and the conditions 
of degradation.[125] Its rubbery features, tailorable degradation kinetics and mechanical properties, 
ease of shaping and manufacturing have made PCL, over time, a suitable material to fabricate 
scaffolds for replacing hard tissues, an interesting material for surgical sutures, and micro- and nano-
drug delivery.[127] The biocompatibility of PCL has been proved by non-toxic and non-acidification 
effects in in vivo experiments.[128–130] Structurally, despite its low E in the range of 0.21 – 0.44 
GPa,[119] it has been often used for bone and cartilage grafting and repair being prepared via AM.[131–
134] 
PCL/HA reinforced scaffolds have been fabricated by employing three different additive 
manufacturing techniques: FDM, DIW and SLS. FDM was used to create a replacement for goat 
femurs by using 30 wt% HA, getting a 26% porous structure with 15 MPa of CS and E of 80 MPa. 
In vitro studies showed that the samples seeded with MC3T3-E1 proved good cytocompatibility and 
successful biodegradation.[81] 
Concerning the DIW approach, a first study described a Poly-ε-caprolactone reinforced with HA (20 
wt%) 3D-printed to mimic human molars and rat incisors. In vivo experiments in rodents showed new 
native alveolar bone grown on the implant site.[80] Meseguer-Olmo et al. presented, instead, a scaffold 
made of PCL with nano-crystalline silicon-substitute HA (nano-SiHA) with demineralized bone 
matrix. They employed DIW to deposit a polymerized slurry. Before testing the samples in vivo on 
  20 
rabbits, the construct was dried at 37 °C and sterilized by UV. The post-implant assessment showed 
excellent osteoconductive and osteointegration properties along with high histocompatibility with the 
host tissues.[82] Alternatively, Russias et al. focused their study on the mechanical properties of 
PCL/HA constructs (HA 70 wt%) made by DIW. Results revealed how the E in parallel to the printing 
plane (i.e., E = 110 ± 20 MPa) differed from that in perpendicular it (i.e., 24 ± 5 MPa) without further 
biological investigations (Figure 5).[77] 
 
Figure 5. SEM micrograph of a PCLA/HA (HA 70 wt%) scaffold where the surface degradation is 
appreciable. Reprinted from [77] with permission – © 2017 John Wiley and Sons. 
SLS was exploited to fabricate replacements able to promote tissue in-growth: by using PCL/HA 
composites, Williams et al. fabricated a porous scaffold (37% porosity) able to perform the envisaged 
task although possessing relatively poor mechanical properties (i.e., E = 67 MPa, CS = 3.2 MPa).[84] 
Weaker results were also achieved in another work (i.e., E = 2.3 MPa, CS = 0.6 MPa) although they 
used HA 30 wt%.[85] More recently, by employing Strontium-HA (SrHA) compounds, Liu et al. 
prepared 3D printed scaffolds with different percentages of reinforcement (0:100 to 50:50 wt%) to 
test in vitro and in vivo the capability of the constructs to promote bone regeneration. The samples 
showed a compressive stress in the order of 7 MPa with E of 40 MPa with fair biological outcomes 
revealing the proliferation and the osteogenic differentiation of the BMSCs seeded into them.[83] 
Poly(ether-ether-ketone) (PEEK) 
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Poly(ether-ether-ketone) or Poly(oxy-1,4-phenylene-oxy-1,4-phenylenecarbonyl-1,4-phenylene) is a 
polyaromatic semi-crystalline thermoplastic polymer, also known as PEEK, which has been 
increasingly employed as material for prosthetics, orthopedics, maxillo-facial and spinal implants. It 
represents an efficient alternative to implantable metal-based devices, due to its versatile mechanical 
and chemical properties that are retained at high temperature, reducing shielding stress after 
implantation: E in the range of 3 – 4 GPa,[135] close to that of the human cortical bone (i.e., 7 – 30 
GPa),[136] and a tensile strength of 90 – 100 MPa.[137] Moreover, it has also radiolucent properties, 
permitting radiographic assessment. 
PEEK-based materials have been considered relatively bio-inert in biological environments, 
demonstrating a weak osteointegration following implantation. For this reason, over the past decade, 
there has been a growing interest in further improving PEEK features to stimulate bone apposition 
for load-bearing orthopedic applications.[138] Scaffolds made of a blend composed of HA and PEEK 
have been fabricated via SLS: the authors performed a sensitivity analysis on the main parameters of 
the SLS (e.g., laser power) along with different percentages of HA powder, from 10 to 40 wt%, with 
diameter size distribution below 60 μm. The optimized constructs were fabricated by fixing the laser 
at 16 W and 140 °C. However, they decided to avoid higher HA percentages (i.e., more than 40 wt%) 
to avoid instability and fragility of the final structure.[86] 
Polyethylene (PE) 
Polyethylene (PE) is a versatile thermoplastic polymer largely employed in the orthopedic field, as a 
load-bearing mean in artificial joints or to treat arthritis.[139,140] It is an inert and hydrophobic material 
that does not degrade in vivo. PE is produced at different molecular weights (Mw) and different 
crystallinity grades. Based on the Mw, PE is classified as low-molecular weight polyethylene 
(LMWPE), high-molecular weight polyethylene (HMWPE), and ultrahigh-molecular weight 
polyethylene (UHMWPE). LMWPE with Mw 50 – 200 kDa and 40 – 50% crystallinity is the softest, 
with E equal to 100 – 500 MPa, mainly used for packaging applications. HMWPE can have similar 
Mw but 60 – 80% crystallinity and E of 400 - 1500 MPa. It has been used to make stable devices (i.e., 
  22 
containers) or for implantations. UHMWPE has Mw above 2000 kDa, 50% – 60% crystallinity and E 
of 1000 – 2000 MPa.[139] In addition to their Mw, HMWPE and UHMWPE have gained much attention 
as load-bearing materials for joint endoprostheses due to their chemical inertness, mechanical 
strength, limited tissue reaction, and biostability.[140] Furthermore, it was observed that it is possible 
to tune the wear resistance in UHMWPE by varying the grade of crosslinking, in order to make the 
material more suitable for specific applications.[141] 
To enhance the biocompatibility of PE, researchers have explored the use of PE as a matrix with HA, 
developing composites with improved features. Most of the PE/HA composites have been fabricated 
via extrusion technologies, non-AM driven, without any specific control of the macro-topology.[142–
149] Alternatively, Hao et al. investigated the development of a structure made of HDPE reinforced 
with HA (at 30 – 40 vol%) made by a CO2 SLS (spot = 193 μm, wavelength = 10.6 μm, focal length 
= 491 mm). They highlighted how this specific AM process plays a role in the key features of the 
composite, affecting the fusion of HA particles, enhancing their bioactivity, and finely tuning the 
pores size, reaching 200 – 400 μm pores with an optimized laser power of 2.4 W at 1200 mm·s-1 
scanning speed.[87] 
Polyamide (PA) 
Polyamides (PAs) are semi-crystalline and thermoplastic aliphatic polymers, frequently referred to as 
Nylons, which contain recurring amide groups (R—C(=O)—NH—R’) as integral parts of the main 
polymer chain. Synthetic PAs are typically produced by poly-condensation of diamines with 
dicarboxylic acids or esters. The aliphatic polyamides have been widely used as biomaterials for drug 
delivery or adhesives to be coupled to porous structures.[150] The relative high stiffness (i.e., E = 3 
GPa),[151] the shape-holding features, the ease of processing, and the low biodegradability make them 
suitable for many biomedical applications, ranging from soft and flexible tubing and catheters to 
strong and stiff components for orthopedics and dental surgery.[152] Moreover, PAs have good 
biocompatibility with human tissues, probably due to their similarity to collagen protein in chemical 
structure and active group.[153] 
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Their high polarity gives to the PAs a relatively high affinity to form hydrogen bonds with nano-sized 
HA.[154] Nanoscale PA/HA scaffolds have been traditionally manufactured to reconstruct craniofacial, 
extremity and spinal column bone tissues via precipitation[155,156] or thermally induced phase 
inversion processing technique.[157] Porous n-HA/PA66 scaffolds were produced by thermal pressing 
and injection after preparing a mold by Xu et al. via SFF. They obtained 3D composites with pores 
size ranging between 300 – 500 μm, suitable for bone application, characterized by a very high CS 
(i.e., 117 MPa) and E of 5.6 GPa, features close to the actual bone.[158] They demonstrated that the 
new bone matrix was able to gradually creep into the interconnected porosity of HA/PA66 scaffolds, 
being embodied into the host tissue, without any fibrous tissue after 2 weeks, after both intramuscular 
and endosseous implantations in white rabbits (Figure 6).[89] 
 
Figure 6. Observations at 2, 4, 12 and 26 weeks after (a-d) intramuscular and (e-h) endosseous 
implantation of PA66/HA scaffolds. Reprinted from [89] with permission – © 2011 Open Access, Dove 
Press. 
Li et al., instead, exploited DIW to develop PA /nano-HA constructs to enhance the mandibular bone 
augmentation after a preliminary three-dimensional modelling of the anatomical structures supported 
by Computed Tomography (CT). 
Poly(methyl methacrylate) (PMMA) 
Poly(methyl methacrylate) is an amorphous non-biodegradable thermoplastic material, approved by 
the FDA, used for reconstructive surgery applications such as in situ formed bone cement or pre-
surgically shaped bone implant in the craniofacial area. PMMA is one of the amorphous polymers 
belonging to the acrylate family, which can be in situ polymerized from a slurry containing PMMA 
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and methyl methacrylate monomers.[159] PMMA-based bone cements can be mixed with inorganic 
ceramics, or bioactive glass, to modulate curing kinetics and enforce mechanical properties. 
Commercially available PMMA-based bone cements, in the form of solid mold, are characterized by 
CSs of 85 – 100 MPa, which is close to cortical bone compressive strength ranging from 130 to 180 
MPa.[160] However, the main drawbacks limiting their surgical application include: a high exothermic 
polymerization temperature, which can reach values as high as 40 – 56 °C,[161,162] a cement shrinkage 
of around 6 – 7% during the curing process in vivo,[161] presence of unreacted monomers, and 
relatively long operation times increasing the risk of infection and tissue necrosis. 
Very little effort has been carried out on PMMA/HA composites, probably because of the non-
biodegradability of the PMMA itself. Lee et al. investigated the use of SLS on a slurry composed of 
HA powder coated with PMMA and methanol,[91,92] achieving constructs with adequate porosity (i.e., 
30% with pores size of 40 -100 µm). Although interesting, these papers did not report specific 
information on the mechanical properties of the scaffolds and/or any biological application/test to 
evaluate its performance with other tissues. 
Soft matrix-based biocomposites 
Soft matrix composites are mainly represented by hydrogel-based materials that are typically 
processed by extrusion-based AM technologies. Due to their nature, these soft-based composites are 
generally printed in a phase with a liquid-like predominant behavior. Subsequently, the printed HA-
reinforced soft matrices usually undergo a post-processing step that allows the promotion of the long-
term stability for the printed structures at physiological conditions. These procedures are mainly 
dependent on the printed material and great efforts have been made by several authors to identify the 
optimal crosslinking strategy for each material candidate (Figure 7) as described in detail in the 
following paragraphs. 
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Figure 7. Extrusion-based printing of HA-reinforced soft composites. The biomaterial ink is loaded 
in the cartridge of a 3D printer and printed to obtain the scaffold. Next, the printed structure is post-
processed to stabilize the printed structure with a procedure optimized for the printed material. (a) 
Alginate is printed and, generally, immersed in a cationic bath to ionically crosslink its negatively 
charged groups. (b) Collagen is usually printed and then crosslinked through the activation of 
intermolecular bonds between aldehydes and other collagen amino acids with a crosslinker. (c) 
Gelatin is printed and, generally, chemically crosslinked by covalently binding its functional groups. 
(d) Chitosan is printed and, generally, immersed in an alkaline solution (pH > pKa) to chemically 
crosslink its positively functional groups. 
The great interest in printing soft-matrix-HA-reinforced biomaterials relies on the possibility of 
simultaneously loading in the printed hydrogel, in addition to the HA reinforcement, cells and/or 
bioactive molecules to stimulate their proliferation/differentiation or a desired in vivo response (Table 
5). 
Table 5. Soft matrix-based hydroxyapatite reinforced composites: structural, morphological and 
biological properties. For all the considered literature works, scaffolds are typically printed by layer-
by-layer deposition of 0-90° shifted filaments. *HA-reinforced PVA was fabricated via SLS. 
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[95] 
  26 
(C3H
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alginate 
ink 
E = 2 – 10 
kPa 
- 
MC3
T3-
E1 
Viable cells 
successfully 
bioprinted. 
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Alginate 
Alginates constitute a family of polysaccharides naturally present in seaweeds or as bacterial 
exopolysaccharide. The alginate structure is composed by a linear repetition of 14 linked -D-
mannuronic acid (M) and -L-guluronic acid (G) units, with 4C1 ring conformation. The percentage 
and sequential distribution of G and M blocks (i.e., MMMM, GGGG or MGMG) determine alginate 
properties. Extraction of alginic acid from the selected natural source (typically seaweeds) is 
performed by removal of counterions, by immersion in mineral acid, and subsequent neutralization, 
by immersion in alkaline solution. Extracts are then filtered, washed and precipitated to obtain water-
soluble sodium alginate.[163] Alginates form hydrogels in the presence of divalent cations, such as 
Ca2+ and Mg2+, due to the interaction of positive charges of ions with the negative charges on the 
alginate polymer chain leading to the so called “egg-box” structure. 
Alginate hydrogels find extensive applications in the biomedical field, including drug delivery, 
protein delivery, wound dressings and tissue engineered scaffolds thanks to their proved  
biocompatibility.[164,165] The main drawbacks associated with the use of alginate-based hydrogels are 
the non-degradability in mammalians, the lack of intrinsically available cell-adhesive motifs (i.e., 
biological inertness) and their poor mechanical properties, typically < 500 kPa.[166] To overcome these 
limitations, oxidation of alginates was proposed by several authors to induce susceptibility to 
hydrolytic degradation.[167,168] Cell-adhesive motifs have been used to decorate alginate polymer 
chains by covalent binding of RGD peptides (Arginine-Glycine-Aspartate aminoacidic sequence) to 
promote the adhesion of cells by integrin-mediated binding and cell-matrix crosstalk.[169] Composite 
alginate hydrogels can be obtained by addition of micro/nano particles (e.g., iron oxide 
nanoparticles)[170] or fibers (e.g., PLA sub-micron fibers)[171] to the alginate hydrogel to improve its 
rheological properties and mechanical performance. Alternatively, the use of alginate-HA composites 
has been proposed to increase the hydrogel mechanical properties and improve the biomaterial-cells 
interaction, especially to target bone tissue regeneration. In particular, several authors have described 
the combination of alginate with HA to achieve ECM-biomimetic composites as scaffolds for bone 
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regeneration; the addition of HA is performed to improve cell adhesion to the scaffold, its 
osteoconductive properties, and the hydrogel mechanical properties.[172] Moreover, HA reinforcement 
fosters the hydrogel radiopacity enhancing the visualization of implanted scaffolds by medical image 
analysis, including micro-CT.[96] 
Alginates are among the most used hydrogels for the production of biomaterial inks and bioinks: in 
fact, mild crosslinking conditions, low costs, shear thinning properties, hydrophilicity, and fast 
gelation, which typically occurs in minutes, make alginate the optimal candidate for bioprinting 
processes.[173,174] Despite different AM technologies have been used for alginate processing, 
including droplet-based printing [175,176] and LAP,[177] alginate-based hydrogels and, in particular, 
alginate-HA composites are mainly processed by extrusion-based technologies.[178,179] 
Alginate/HA composites can be customized to achieve rheological properties suitable for extrusion-
based printing properties. Specifically, the alginate solution rheological properties can be increased 
by increasing the alginate concentration or by lowering the solution temperature.[180] The typical 
approach to print alginate composite filaments (i.e., diameter of 100 – 500 µm) is based on the 
extrusion of an alginate solution (i.e., typical concentrations 1.5 – 4% w/v) loaded with HA particles, 
in concentrations up to 20% w/v, and subsequent immersion in a divalent ion bath (i.e., typically 100 
– 200 mM CaCl2 solution). Alternatively[97] or complementarily to external gelation,[110] internal 
alginate gelation can be used by printing the alginate solution during its ongoing crosslinking process 
by adding CaSO4 to the alginate ink before printing. Despite the intrinsic optimal properties of 
alginate solutions for extrusion-based printing, several studies have described the addition of gelatin 
to the bioink to further improve the printed shape maintenance immediately after printing.[96,98] In 
fact, HA-reinforced alginate/gelatin composites are largely printed on cooled substrates to promote 
temporary gelatin gelation (T < Tsol-gel gelatin) due to low temperatures and subsequently immersed in 
divalent ion bath to stabilize the shape for the long term by alginate crosslinking.[93] Alternatively, 
some authors[94] investigated the possibility of forming in situ HA after the immersion of Na2PO4-
loaded alginate hydrogel in CaCl2 solution: despite the HA formation having mainly been achieved 
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on the outer shell of the printed filaments, this method represents an interesting alternative to the 
direct loading of HA into the printed ink (Figure 8). 
 
Figure 8. In situ mineralized bioprinted alginate scaffolds. Nano-HA enucleated on the alginate 
printed filaments (stereomicroscopy images, top-left, and SEM micrographs, top-right and bottom-
left). Bone marrow-derives mesenchymal stem cells adhered and spread on the printed scaffold 
(bottom-right). Reprinted from [94] with permission – © 2015 American Chemical Society. 
Despite several authors having reported an improvement of mechanical properties of alginate 
hydrogel scaffolds loaded with HA and fabricated by traditional methods, including freeze-
drying,[172,181] only slight increases of the mechanical properties have been achieved, so far, for 3D-
printed alginate-HA composites. In fact, an increase of the mechanical properties of printed alginate 
is generally observed, when loaded with HA, immediately after printing or in the dry state. However, 
after immersion in water or culture medium, the effect of HA addition on the mechanical properties 
is generally negligible: typical values for the compressive E are in the range of 10 – 30 kPa.[93,94,97] 
However, authors agree on the fact that improvements in the hydrogel mechanical properties can be 
expected after the deposition, by seeded cells, of inorganic ECM also promoted by HA constructs.[93] 
Improved osteogenesis of stem cells encapsulated in HA-reinforced alginate hydrogels has been 
proved in several works: HA is able to alter DNA methylation with the consequent modification of 
gene expression of an osteogenic phenotype. For instance, Wang et al. demonstrated that hASCs were 
characterized by the increased expression of osteogenesis-related genes (i.e., OCN and RUNX2) in 
nanoHA-loaded alginate hydrogels with respect to plain alginate hydrogels. Similarly, Demirtaş et 
al. proved an increase of osteogenic gene expression (i.e., OCN, OPN) of MC3T3-E1 cells loaded in 
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alginate/HA bioinks compared to printed neat alginate.[110] By using a different approach, Luo et al. 
nucleated HA on the surface of 3D-printed alginate hydrogels by in situ mineralization [94] and 
observed an increased number of hBMSCs attached to the printed scaffolds, compared to printed 
alginate hydrogel without HA. Moreover, the presence of HA increased the intracellular levels of 
ALP activity, thus proving the increased functionality of the printed alginate when loaded with HA. 
The improved osteogenesis of HA-loaded 3D-printed alginate hydrogels, proved by in vitro tests, is 
also reflected in the osteoconductive properties of HA and ability in promoting the formation of new 
healthy bone once the scaffolds are implanted in vivo. For instance, alginate/HA biocomposites 
loaded with hASC were subcutaneously implanted in vivo in nude mice, after 7 days of osteogenic 
induction in vitro. The alginate/HA biocomposites were not only able to promote more bone tissue 
formation compared to plain alginate hydrogels, as proved by micro-CT imaging, but also to achieve 
bone formation throughout the whole printed construct, compared to pure alginate that promotes new 
bone formation only around the printed scaffolds pores.[96] To further improve the in vivo 
osteogenesis, alginate/HA biocomposite bioinks have been loaded with biomolecules/drugs that 
promote in vivo formation of bone tissue. For example, alginate/HA composite inks were loaded with 
Atsttrin, a Tumor Necrosis Factor (TNF)-α inhibitor, to reduce the inflammatory response after 
scaffold implantation. In this study, not only was the alginate/HA construct shown to improve bone 
formation in an in vivo calvarial mice defect, but the successful incorporation and subsequent release 
of Atsttrin from the printed scaffold was shown to modulate the local inflammatory response, thus 
further improving the bone healing process.[95] 
Collagen 
Collagen is a natural polymer widely present in the human body and, generally, in animals: from teeth 
to connective tissue, it represents the main component of numerous soft and hard tissues since it is 
the main constituent of the natural ECM.[182,183] Scientists have identified twenty-eight different 
polymers that, based on their structure, may be recognized as collagen. Collagen Type I, the most 
abundant, is one of the main components of the bone, being part of up to 89% of its organic matrix 
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and 32% of its volumetric composition.[184] Collagen Type I also contains the RGD and Asp-Gly-
Glu-Ala (DGEA) sequences that mediate cell binding via integrin receptors.[185–187] Other types of 
Collagen are Type II that has been found in cartilage as well as specific tissues of the auditory 
apparatus (i.e., the tympanic membrane) or Type III that composes the blood vessel walls.[41] 
Collagen is a biodegradable and osteoconductive biomaterial[41,42] that provides natural attachment 
for cells.[188,189] Additionally, it represents an excellent natural carrier for bioactive molecules or 
drugs,[190,191] able to inhibit bacterial pathogens growth.[192] Despite its remarkable properties, 
collagen needs to be treated by crosslinking to improve the mechanical properties when hydrated,[193] 
specifically the stiffness (i.e., E in the order of 100 MPa),[194] that in most of the applications in tissue 
engineering is not adequate to bear the mechanical loads. On the other hand, besides improving E and 
resistance to enzymatic digestion,[195] chemically crosslinked collagen fibers can be potentially toxic 
due to residual molecules or compounds used for the crosslinking; thus; dehydration is generally the 
preferred alternative.[196] 
Concerning bioengineering applications (e.g., tissue repairs and/or replacements), collagen derived 
from animals, especially bovines, is the most commonly used material due to its availability although 
it may elicit antigenic response.[197–199] Processing methods mainly include SFF to fabricate molds 
where to cast a HA-based blend, since its high viscosity makes difficult a direct 3D printing. In order 
to exploit the AM techniques, researchers have been employing chemical solvents to reduce the 
viscosity. However, since the effect of these solvents is still limited, the actual quantity of collagen 
in the biomaterial inks is limited.[99,200] 
Collagen (typically Type I), is often reinforced with HA to achieve a biomimetic composite similar 
to bone. The reinforcement of the polymer through the HA ceramic structure enhances specific 
features for applications in surgery such as adaptability and shape control, clot facilitation and 
stabilization,[201] and higher degradation rate (i.e., 2 months vs. 2 years) with respect to the traditional 
polymeric scaffolds.[202] Additionally, porosity can be tailored by controlling the freezing rate, 
temperature and collagen concentration.[203–210] Being compatible with both humans and 
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animals,[201,211] collagen/HA structures possess biological advantages compared to synthetic 
polymeric scaffolds.[212] Concerning bone regeneration, it has been demonstrated that both the 
composite constituents, singularly, are able to promote osteoblast differentiation but osteogenesis is 
accelerated when they are mixed.[213] Osteogenic cells appeared to better adhere, in vitro, to collagen 
surfaces instead of PLLAs and PGAs.[214] Furthermore, osteoconductivity is fostered if the composite 
is compared to monolithic HA.[211,215] 
From a mechanical point of view, this biomaterial is able to balance the fragility of the HA with the 
ductile properties of the collagen allowing a better stability and resistance of the composite.[216,217] In 
order to evaluate the mechanical properties of the collagen/HA constructs, MD models have been 
coupled to experimental assessments in which researchers aimed at understanding the role played by 
HA content, morphology, porosity, pore architecture, and fabrication methods.[204,218–223] Among all 
the key features, Currey et al. demonstrated that high percentages of HA coupled with a reduced 
porosity of the scaffold may lead to higher values of E and ultimate strength.[224] At the same time, 
the collagen matrix acts as a load transfer medium to the rigid part (HA) deposited in its voids between 
tangled crosslinked fibers.[222,223] Collagen, hence, mechanically interacts with HA reinforcements by 
calcium ion bridges, leading to an increase of the composite resistance.[225] HA particles act as local 
stress concentrators in the collagen fibrous network and when the collagen fibers try to align on the 
direction of the stress, the material close to the HA particles gets a significant increase of the stress 
that can lead to fracture with a parallel reduction of the ultimate strength and final deformation.[188] 
Different types of collagen/HA composites have been developed by scientists with diverse 
manufacturing approaches: dense[226–229] or porous materials,[209,215,218–220,230] or composites with 
elongated and plated-like HA crystals.[231] Different approaches have led to different results in terms 
of mechanical properties. For instance, a recent study employing HA whiskers to reinforce the SFF 
manufactured scaffold exhibited a nearly four-fold greater modulus compared to the equiaxial HA 
powder (i.e., HA 44 wt%). At the same time, no significant differences at higher and lower 
reinforcement levels were observed.[232] 
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The main challenge in fabricating collagen/HA scaffolds is related to the high viscosity of the 
composite that, as detailed above, can be partially overcome by using chemical solvents but, on the 
other hand, make difficult any inclusion of bioactive molecules[233]. These latter are, hence, mostly 
used to make surface coatings after the scaffold fabrication.[234,235] Due to these difficulties, the most 
pursued approach for producing collagen/HA structure is the indirect application of AM, namely SFF. 
In[100], the authors prepared a composite made of Collagen Type I and HA particles prepared with a 
freeze-drying procedure. After replacing the ice crystals with ethanol according to literature,[3,236] a 
dehydrothermal (DHT) crosslinking was performed. In this case, a slurry of material composed of 
3% w/v suspension with equal parts in weight of collagen and HA microspheres in a water solution 
of 0.3 w/w acetic acid was cast in plastic molds to produce disk-shaped scaffolds. The constructs 
revealed larger pores (i.e., diameters up to 200 μm) than those found in unmineralized collagen 
scaffolds. From a mechanical point of view, the compressive modulus was 1.7 times, at low strains, 
and 2.8 times, at high strains, greater than that of collagen, reaching at most 50.74 kPa. After seeding 
cells, they showed a round shape, like healthy osteocytes, in the composite while in neat collagen 
structures they exhibited a more elongated geometry (Figure 9). Another attempt was carried out by 
Crystal et al. where collagen reinforced with HA flakes (i.e., 1% w/v) was cast into 3D-printed 
sacrificial molds post-degraded with ethanol, leading to an interconnected and branched porous 
structure with micro-channels up to 800 μm in width.[101] 
 
Figure 9. SEM micrographs for (a, b) pure collagen and (c, d) collagen/HA scaffolds. Scale bars: 
(a,c) 100 μm, (b,d) 20 μm. Reprinted from [100] with permission – © 2016 Elsevier. 
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A different approach was explored by Lin et al., that used DIW to fabricate three-dimensional 
constructs at low temperature thanks to the recently-developed filament-free printing technique 
(Figure 10B-E).[99] With this technique, collagen and HA were mixed before printing (i.e., 1:2 w/w 
at 4 °C) in order to create structures with rods with a diameter range of 300 – 900 μm, where bioactive 
molecules could be included without any effect on their natural properties. In this case, the 
crosslinking was performed with 1% w/v genipin solution and sterilization was performed by ethylene 
oxide.[237–239] Although the prepared scaffold enhanced the BMSCs osteogenic proliferation and 
differentiation, the compressive modulus did not meet the value of the softest bone: 0.1 MPa vs. 2-
20 MPa.[76] 
 
Figure 10. (Left) Macroscopic view of the surface morphology of the experimental collagen/HA 
(CHA) composite scaffolds. (B) Scaffolds had a microstructure with pore size of 400 μm and rod 
widths of 300 μm (group I), 600 μm (group II), or 900 μm (group III). Group IV was nonprinted 
scaffolds. (C -E) Macrostructures mimicking human bones fabricated via DIW. Scale bar: 5 mm. 
(Right) SEM images of BMSCs on the surface of the scaffolds at 1, 4, 7, and 11 days after seeding in 
vitro showing cell growing in the constructs after 11 days from seeding. Reprinted from [99] with 
permission – © 2016 American Chemical Society. 
Gelatin 
Gelatin is a water-soluble protein derived from the partial hydrolysis of collagen. Gelatin polymers 
with different Mws and isoelectric points can be obtained from different animal tissues - typically 
porcine, bovine or fish – treated through an extraction process (i.e., alkaline or acidic collagen pre-
treatments). The outstanding advantages in the use of gelatin as a naturally-derived polymer for tissue 
engineering applications rely in the exposure of cell-ligand motifs (i.e., RGD) which promote cells 
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adhesion to gelatin by integrin-mediated interaction, and target sequences for metalloproteinases 
(Mitochondrial Processing Peptidase - MPP), which promote the in vivo enzymatic degradation and 
ECM remodeling. Moreover, compared to collagen, gelatin provokes less immunogenic and antigenic 
response after in vivo implantation. Furthermore, the popular use of gelatin for tissue engineering 
applications has been also due to its versatility, ease of availability and low cost.[240] 
After dissolution in water, the gelatin solution is characterized by thermo-responsive properties. In 
fact, the gelatin solution undergoes a sol-gel transition at sol-gel temperature (Tsol-gel) ≈ 30 °C, 
depending on the specific gelatin properties and concentration; the solution is characterized by a 
liquid-like behavior at a temperature T > Tsol-gel, while it is characterized by a solid-like response for 
T < Tsol-gel. Thus, at 37 °C (i.e., in vivo temperature) the liquid-like response is predominant, not 
suitable for sustaining tissue regeneration by three-dimensional scaffold approach. Thus, crosslinking 
strategies must be used to improve the mechanical properties and stability of gelatin at T > Tsol-gel. 
Several approaches have been widely described including physical,[241] non-zero-[242] and zero-
length[243] chemical, and enzymatic[244] crosslinking mechanisms that showed successful outcomes in 
generating biocompatible gelatin hydrogels for a variety of tissue engineering applications. 
The abovementioned advantages of gelatin, together with its well-known thermo-responsive 
behavior, have made it one of the most popular materials for the production of ink and bioinks for 
extrusion-based processes. In fact, the thermo-responsive properties of gelatin can be smartly 
exploited by loading the gelatin solution in a printing cartridge (T > Tsol-gel) and printing on a cooled 
substrate (T < Tsol-gel) to temporarily fix the printed shape. Lastly, the printed construct is crosslinked 
to fix its long-term shape maintenance and improve stability at 37 °C. This printing strategy is by far 
the most used when considering additive manufacturing processes described to print gelatin/HA 
hydrogel inks. 
Gelatin/HA biocomposites have been proposed for bone tissue engineering thanks to the joined 
advantages of the gelatin structure in mimicking the collagenous structure of bone and the inorganic 
HA particles that mimic the mineral bone component.[245] A few examples have described the use of 
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such composites as biomaterial inks/bioinks by extrusion-based processing for the production of 3D-
printed scaffolds (Figure 11). 
 
Figure 11. 3D printing of HA-reinforced gelatin ink-based scaffold. Reprinted from [104] with 
permission – © 2015 Elsevier. 
The combined use of gelatin and loaded HA can recreate an ideal microenvironment for cells 
adhesion, proliferation and differentiation towards osteogenic phenotype, given by the presence of 
intrinsically cell-adhesive motifs of gelatin and the inorganic component represented by HA, together 
with improved mechanical properties given by the reinforcement of HA to sustain bone regeneration. 
Within the printing strategies, a controlled temperature for the extrusion-based process is generally 
required: in fact, literature works have described the printing of HA-loaded gelatin hydrogels by using 
a printing cartridge kept at T > Tsol-gel and, generally, a printing plate with controlled temperature, T 
< Tsol-gel since the thermo-responsive properties of gelatin hydrogels have been demonstrated to be 
not affected by the addition of HA.[105] Moreover, the addition of HA to the ink has been shown to 
improve the rheological response to shear stress by increasing the viscosity of the HA-loaded 
hydrogel; for instance, the principal rheological parameters (i.e., viscosity, G’ and G’’) were 
demonstrated to significantly increase after the addition of HA to the gelatin ink,[102] thus improving 
the shape definition of the printed scaffolds. The addition of a 2:1 ratio of HA to a 25% w/v gelatin 
solution more than doubles the complex viscosity η* of a gelatin ink and improves the shape definition 
of the printed solution compared to gelatin without HA, as shown by the printed filament circular 
cross-section obtained when printing the HA-loaded hydrogels compared to the collapsed filaments 
obtained by printing the neat gelatin solution.[105] 
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The addition of HA to the gelatin inks has been reported to influence not only its rheological 
properties, but also to improve the structural properties of the printed scaffolds with a generally 
proved increase of the mechanical properties comparing the HA-loaded hydrogels to the neat gelatin 
hydrogel. For instance, Huh et al.[105] demonstrated an increase of the compressive elastic modulus 
in gelatin hydrogels loaded with HA, printed and crosslinked by carbodiimide crosslinker - 1-ethyl-
3-3-dimethylaminopropylcarbodiimide hydrochloride (EDC) (i.e., E ≈ 0.4 MPa) when compared to 
the same hydrogel without HA (i.e., E ≈ 0.1 MPa), both in the dry and wet state. Despite the obtained 
compressive modulus values being lower than that of spongy and compact bone (i.e., E ≈ 0.05 – 0.5 
and 14 – 20 GPa, respectively)[245] even after the addition of HA, other authors demonstrated that the 
in vitro culture and osteogenic differentiation associated with cells inorganic ECM deposition 
increased the rheological properties of the printed scaffolds. Thus, even if the starting mechanical 
properties are lower than those of native bone, in vitro culture increase the structural properties of the 
scaffolds to target those of native bone, particularly significant when HA was loaded in the scaffolds 
before cell culture.[246] 
In fact, authors working on HA-reinforced gelatin inks agree that, as demonstrated for other soft 
biocomposites (e.g., alginate), the addition of HA in the printed gelatin scaffold can promote cells 
osteogenesis, accomplished by osteogenic gene expression and inorganic matrix deposition. For 
instance, not only did HA-loaded gelatin hydrogels improve MG63 proliferation, which was possibly 
referred by the authors as a consequence of increased roughness obtained by addition of HA, but cells 
also showed increased ALP activity and OCN gene expression,[105] thus confirming the improved 
osteogenic effects of loaded HA. The observation made by using cell lines was then confirmed by 
more representative models using patient-derived ASCs, loaded in the gelatin-HA bioink, printed by 
micro-extrusion and crosslinked by UV curing (i.e., methacryloyl gelatin), which showed bone matrix 
production (i.e., ALP and OCN immunostaining) after 14 days of culture. 
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Chitosan (CH) 
CH is a naturally derived polysaccharide obtained from the alkaline N-deacetylation of insoluble 
chitin. It is chemically composed of β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine 
polysaccharide units.[247] The ratio between the two units is defined as degree of N-deacetylation. The 
presence of amino groups in the CH structure makes this polymer different from chitin, conferring it 
many peculiar properties. Indeed, for pH below its pKa (i.e., pH < 6.2), the amino groups (NH2) on 
the CH chains are protonated into positively charged groups (NH3
+) making it soluble.[248,249] By 
increasing pH, the amine groups become deprotonated to form insoluble CH polymer, which tends to 
produce a physical hydrogel thanks to reversible interactions (e.g., electrostatic, hydrophobic or 
hydrogen bonds) that can occur between polymer chains. This soluble-insoluble transition, at its pKa 
value, depends on the degree of N-deacetylation and Mw of the polymer.
[165,250] CH is considered as 
an appropriate functional material for biomedical applications due to its intrinsic properties: excellent 
biocompatibility, controlled biodegradability with safe by-products, antimicrobial and hemostatic 
properties.[248] The use of CH alone is mainly devoted to skin, nerves and soft tissue 
regeneration,[247,251] but the structural similarity of CH backbone to glycosaminoglycans, the main 
components of bone ECM, renders it able to support cell attachment and proliferation favoring 
chondrogenesis and bone tissue regeneration.[247,252] However, CH is a soft biomaterial characterized 
by low mechanical resistance, especially under hydrated conditions, which represents one of the main 
limitations in using it without the addition of other components. CH efficiently complexes metal ions 
or nanoparticles,[253] natural or synthetic anionic species (such as lipids, proteins, DNA), 
polyelectrolytes (such as tripolyphosphate), or is blended with other polymers[254] or functionalized 
with bioactive agents[255,256] to enhance its mechanical properties. This was also achieved by 
integrating bioceramics, in particular HA, into the CH matrix for scaffolding fabrication, showing 
that CH/HA scaffolds were characterized by a significant enhancement of mechanical strength with 
an increased osteoconductivity.[257–259] It has also been demonstrated that the addition of HA into CH 
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scaffolds improved cell attachment, favoring a higher proliferation and a well-spread morphology 
when compared to the CH scaffolds alone.[260] 
Within the recent years, CH has gained much attention for 3D scaffolds production with highly 
reproducible and controllable pore structure by AM due to its attractive properties, particularly its 
easy processability.[250,261] However, such AM approaches used for natural polymers require 
crosslinking treatment during or at completed printing process, because these water-soluble polymers 
are generally too soft to support their own structures after the printing process.[262] For this reason, 
most of the works reported in literature have been focused on the optimizing of CH-based hydrogel 
composition and rheological properties,[262,263] to make it a more easily printable polymer by 
extrusion-based approaches. For example, Lee et al. reported the production of highly porous CH 
scaffolds by extruding the chitosan solution onto a cryogenic plate held at -20 °C, and finally freeze-
drying. They obtained a porous structure inside the filaments with relatively weak mechanical 
properties (i.e., E of 1.2 MPa and maximum tensile strength of 0.16 MPa for a dried scaffold).[264] 
Regarding the production of 3D CH-based scaffolds reinforced with HA by AM, a preliminary 
attempt was described by Ang et al. who fabricated CH/HA composites by using a rapid prototyping 
robotic dispensing (RPBOD) system where solutions of CH/HA were extruded through a small 
Teflon-lined nozzle (internal diameter 150 μm) into the dispensing medium (i.e., NaOH–ethanol) to 
form a CH gel-like precipitate.[106] 3D printed CH/HA scaffolds showed a good attachment between 
layers, forming a regular and reproducible macro-porous structure, fully interconnected, with pore 
size ranging between 200 – 400 μm. The high uniformity of the structure was likely due to the 
enhancement of mechanical strength given by the HA reinforcement, which allowed the scaffolds to 
hold their shape during the shrinkage phase in the dispensing medium. In vitro studies revealed a 
healthy morphology and a strong proliferative activity of osteoblasts seeded into the 3D-printed 
constructs. However, no data concerning the mechanical properties of the 3D-printed scaffolds were 
reported in the study and the main limitation of this technique was related to the formation of 
precipitated lumps in the nozzle. Additionally, this method suffers from the high sensitivity to CH 
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concentration on the nozzle tip. During the process, the precipitation starts at the gel/dispersing 
medium interface immediately upon exposure, producing clots. The plotting CH-based material 
tended to solidify before it contacted base layer, resulting in poor adhesion and failure to hold the 
layers.  To overcome these limitations, subsequently, Geng et al. improved the printing technique for 
the CH alone, by introducing a double nozzle system, allowing the sequential extrusion of CH and 
NaOH solution during the fabrication process.[107]  The dual extrusion method eliminated the high 
sensitivity to material concentration compared to the previous work[106], because the precipitation 
occurs when the dispensing material and the coagulant medium merge on the base or on the previous 
layer. In this way, there were no precipitated lumps at the nozzle's end and no fluid medium movement 
to affect the shape of the precipitated layers of the scaffold. 
Later, dense and porous cylindrical CH/HA scaffolds were fabricated by using an extrusion-based 
printer. The processing conditions involved the use of lactic acid (i.e., 40 wt%) as binder agent to 
different CH/HA composites (20 – 30 wt% of CH) followed by a post-hardening process, performed 
by incubating the printed scaffolds in NaOH and lactic acid solution at various concentrations, finally 
dried at room temperature. 3D-printed dense CH/HA (25 wt% of CH) showed optimal mechanical 
properties as demonstrated by their high compression strength of 16.32 MPa and Young Modulus of 
4.4 GPa, with a very low porosity, about 37%. A compact layer of CS was observed for structures 
after immersion in 10 wt% lactic acid as binder. The collapse of the porous scaffold, observed during 
the post hardening process, was due to the immersion in a high concentration of solvent solution: 
therefore, the fabrication of 3D-printed CH/HA scaffolds for tissue engineering, whilst promising, 
still requires further optimization.[108] 
Moreover, as the polymer coating on ceramics may hinder the exposure of the ceramics to the scaffold 
surfaces, the etching of scaffold surface could improve the hydrophilicity, the roughness and the 
surface chemistry of the scaffold, increasing the affinity of the composite towards cells. Thus, some 
studies have recently reported the production of CH scaffold reinforced with HA by AM coupled with 
surface plasma etching treatment. In particular, [109] fabricated 3D CH scaffolds containing 10 and 
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20% HA by using an air extrusion-based plotter. They showed a good porosity and interconnected 
structure, with a pore size ranging from 200 to 500 µm, while the increased hydrophilicity and 
bioactivity on the surface, exposed by plasma etching, enhanced MC3T3-E1 pre-osteoblast cell 
proliferation and differentiation. In particular, CH/HA (10% HA) scaffolds etched with N2 plasma 
significantly improved MC3T3-E1 cell proliferation whilst CH/HA (20% HA) scaffolds etched with 
O2 plasma showed the highest osteoblastic differentiation until 2 weeks (Figure 12). 
 
Figure 12. SEM micrographs showing (a) CH (b) CH/HA (10 wt%) (c) CH/HA (20 wt%) scaffold 
after freeze-drying untreated and etched with O2 and N2 plasma, respectively. Reprinted from 
[109] 
with permission – © 2016 The Japan Society of Applied Physics. 
In 2017, a similar approach was reported by [111]. In this study, a CH/gelatin/HA scaffold with good 
interconnectivity and porosity was fabricated layer-by-layer by FDM and then its surfaces were 
etched by O2 plasma to improve the roughness and wettability on the scaffold surface. The plasma-
roughened surface enhanced the MC3T3-E1 pre-osteoblast cells’ initial attachment but also their 
proliferation. However, in both cases, no data concerning the mechanical properties of the 3D-printed 
scaffolds were reported. Finally, a different approach was pursued by [66] where scaffolds made by 
SFF and composed of PLLA/CH/HA were compared to CH/HA scaffolds with different compositions 
(see PLA section). 
Demirtaş et al. showed a first attempt of mixing chitosan and HA with cells and bioprinting a 3D 
scaffold. They mixed CH/HA solution (pH: 4.0) with glycerol phosphate disodium salt to generate 
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printable scaffolds based on CH (pH: 6.95 – 7.0), at which MC3T3-E1 pre-osteoblast cells were 
added. Disk shaped hydrogels were printed with the use of an extruder-based bioprinter and held at 
37 °C and 5% CO2 for thermal ionic gelation. CH hydrogels exhibited a higher elastic modulus of 4.6 
kPa that increased approximately 3-fold (i.e., 14.97 kPa) with the addition of HA. Morphologies of 
freeze-dried bioprinted CH revealed a porous structure (i.e., pores diameter of about 200 μm), which 
decreased to approximately 100 μm with the introduction of HA. It was also observed that cells 
printed within CH/HA composite hydrogels were homogeneously distributed inside of the structures 
and showed peak expression levels for early and late stages osteogenic markers particularly in the 
presence of HA.[110] 
Polyvinyl alcohol (PVA) 
Polyvinyl alcohol (PVA) is a water-soluble synthetic polymer, with a linear structure, derived from 
partial or full polyvinyl acetate hydroxylation. The hydroxylation process affects its physical, 
chemical and mechanical properties. In fact, the degree of hydroxylation influences PVA molecular 
weight and solubility, and consequently its swelling behavior and E. A higher degree of hydroxylation 
and polymerization of the PVA induces a lower solubility in water. For this reason, its water solubility 
makes necessary the use of physical or chemical crosslinking agents  (e.g. gamma irradiation, 
glutaraldehyde, genipin and others), for granting structural stability and making PVA easier to process 
as a hydrogel, able to swell in the presence of biological fluids.[265] PVA has been approved by the 
FDA for food packaging, because of its excellent barrier properties when processed in the form of 
films. However, it has been widely used also as a biomaterial for medical device fabrication, due to 
its biocompatibility, non-toxicity, non-carcinogenicity, swelling properties, and bio-adhesive 
characteristics.[266] In fact, it has been extensively proposed as a replacement for cartilage and 
meniscus defects due to its high water content, and rubber elastic physical properties, which make 
PVA a good candidate for load-bearing applications.[265] More specifically, PVA hydrogels have 
exhibited a tensile strength in the range of 1 - 17 MPa[267] and a compressive modulus ranging from 
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0.0012 to 0.85 MPa, which is close to cartilaginous tissue mechanical features (i.e., tensile strength 
of 17 MPa[268] and compressive modulus varying between 0.53 and 1.82 MPa).[269] 
Being processed at temperature used on the SLS, several groups have investigated the use of PVA to 
fabricate porous scaffolds for bone tissue engineering by AM. In[112], the authors approached the 
fabrication of PVA/HA constructs by using SLS on two different raw materials: PVA coated via spray 
drying technique with HA powder (70 wt%) and a slurry of PVA and HA powder – diameter size less 
than 60 μm – with different HA concentrations (%HA varied: 10, 20, 30 wt%). The conclusions of 
this study highlighted how the SLS-machined-blended composite presented the highest porosity with 
a good grade of interconnectivity. Biological tests showed also that the laser employment did not 
affect the bioactivity of the HA in both cases, although the blended mix has to be preferred for tissue 
engineering applications due to its higher compatibility with the host tissues, as demonstrated by tests 
in Simulated Body Fluid (SBF). 
Silk 
Silk is a natural protein fiber possessing high mechanical strength, tunability, controllable degradation 
and manufacturing flexibility as well as good biocompatibility.[270–278] Scientists have been using this 
material for a number of applications including medical sutures, and tissue regeneration since it was 
observed that sericin has some inflammatory effects.[279–286] Despite silk, considering its high 
mechanical properties, can be used as reinforcement to improve the features of soft matrices, it can 
also be used for the production of soft composites and can thus be considered a soft material. 
Very few studies have been carried out on silk-HA biocomposites. In [21], the authors used Direct Ink 
Writing (DIW) to fabricate three-dimensional silk fibroin-HA structures aimed at regenerating bone 
tissues. They fabricated structures (i.e., filament diameter = 200 μm) with pores ranging from 200 to 
750 μm able to promote osteogenesis and vasculogenesis. The high-concentrated HA biomaterial ink, 
deposited at 2 mm∙s-1, possessed high viscosity (i.e., 104 Pa∙s under low shear stresses and plateau at 
105 Pa). Mechanical and biological assessments showed interesting properties including a stiffness of 
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220 MPa for single filaments and a relevant promotion and proliferation of hMSCs seeded for bone 
regeneration (Figure 13). 
 
Figure 13. (a) 3D silk/HA scaffold with gradient porosity. (b) SEM micrograph of printed silk/HA 
filaments: detail of an overlapping of two layers. Scale bar, 100 μm. (c) SEM micrograph of the of 
the silk/HA filament surface. Scale bar 10 μm. (d) Height profile of a representative silk/HA filament 
acquired by AFM. Reprinted from [21] with permission – © 2012 John Wiley and Sons. 
More recently, silk/HA composites were studied by Huang et al. in combination with sodium alginate 
with different mass ratios (i.e., 3:1, 5:1 and 10:1), fabricating via DIW porous cylindrical scaffolds 
(porosity = 70% - pores size = 400 μm) that revealed CSs in the order of 6 MPa. The constructs, tested 
with hBMSCs, showed good biological properties for bone regeneration purposes (i.e., cell adhesion 
and penetration, proliferation and osteogenic differentiation).[113] 
Conclusions and future perspectives 
Regeneration of human tissues by tissue engineering approach is still a very challenging goal since it 
requires the accurate design of scaffolds that sustain the regeneration of the damaged tissue by 
balancing the scaffolds properties, including (i) an adequate structural support and biomimetic 
mechanical properties, (ii) an optimal porosity to allow cell colonization and tissue infiltration, and 
(iii) cyto and biocompatibility. Additive manufacturing techniques have gained tremendous interest 
and success, especially within the last two decades, due to their versatility over fabricating devices 
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from the micro to the macro scale, imposing their advantages (e.g., cost-effectiveness, relative 
inexpensiveness) on the traditional manufacturing processes (e.g., machining). 
Besides the numerous possibilities offered by AM, the fabrication of structures made of a desired 
material, often in combination with other materials (i.e., composites), can represent a challenge due 
to particular requirements and features possessed either by the materials themselves or the process 
itself. This is particularly true in the specific case of HA-reinforced composites, that are used mainly 
as tools to promote/replace cartilaginous and bone structures due to their chemical similarities to the 
native tissues (Figure 14). Besides the matrix used to embody HA, the addition of this hard component 
induces a restriction on the AM options. Specifically, the use of the droplet-based technique has not 
been implemented and all the other approaches, depicted schematically in Figure 2, have suffered the 
limitations caused by the high viscosity of the ink (i.e., hard-matrix-based composites), or the poor 
processability by laser-based techniques (i.e., soft-matrix-based materials). This is why, as also 
summarized in Table 2, there is almost clear division among the HA-reinforced composites with 
respect to the AM techniques. 
 
Figure 14. Deployment of the main features possessed by polymeric scaffolds when reinforced with 
HA.  
Moreover, by considering the composition of the HA-reinforced structures, it appears evident how 
the only class of matrices that has been processed so far with AM is the polymeric one. The main 
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reason may be found in the difficulties in managing metallic-/ceramic-matrix-based materials that 
can be difficult to process due to their poor toughness and high viscosity. 
Polymeric hard-matrix-based composites have been generally preferred as load-bearing 
replacements, due to their higher mechanical properties, in contrast to the soft-matrix-based ones that 
have been mainly proposed for non-load-bearing applications. However, recent trends have shown 
much more interest for the soft materials due to their easier processability and shapeability in addition 
to the possibility to directly load and print viable cells in the compounds, to obtain a uniform cell 
distribution in the printed filaments. Soft materials do, hence, represent the most relevant research 
topic for scientists that, as detailed above, are still developing new strategies to overcome their main 
drawback, namely the poorer mechanical properties (vs. thermoplastic polymers), through different 
crosslinking strategies. 
A detailed analysis and achievement of satisfying mechanical properties still represent, however, a 
frontier: while hard materials may apparently represent a good solution to bear loads, a deep study on 
understanding how each parameter (e.g., %porosity, pores size) acts, especially at the microscale, is 
still missing. Moreover, it remains still unclear how the HA and its features (e.g., size, distribution) 
affect the mechanical properties at cell level. A tool to investigate these issues may be represented by 
an in silico approach where computational modeling at multiple scales could be the key to unveil the 
mechanical behavior of the material, as already demonstrated for the specific case of silk.[275,276,287] 
Another feature little investigated is the vascularization of the HA-reinforced scaffolds: it is clear that 
an interconnected porosity represents a necessary condition for vascularization, but few studies have 
evaluated the capability of the constructs to allow the flows of nutrients needed to avoid the necrosis 
of the tissues and the embodiment in the host site.[288–290] 
From a biological point of view, many degradation studies have been carried out that, however, have 
not achieved a precise control of the phenomenon. A balanced degradation of the scaffold is 
fundamental, indeed, for a correct regeneration of the tissues, reducing the inflammatory response 
and granting an adequate mechanical stability throughout the process of tissue regeneration. 
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Furthermore, many studies showed how the development of such HA-reinforced tissues is supported 
by successful in vitro tests. However, biological tests are generally still missing in vivo validation, 
whose results may confirm, or not, the laboratory tests. 
In addition to the scientific aspects, some translational and ethical issues must be considered in the 
very near future. Developing new scientific and technological products has become really challenging 
due to the high research costs coupled to the increased reduction of external funding and grants. In 
vitro tests, although successful, cannot be the last step in this research field: the lack of the 
aforementioned in vivo studies is mainly due to the increased high costs to be faced when the 
experimentation is moving towards human clinical trials. 
From a legislative point of view, due to rapid development of the AM technologies for biomedical 
constructs, there is an increasing need for a robust national/international regulation on how to 
develop, sterilize and promote the use of these new engineered materials.[291] Recently, the FDA has 
released specific guidelines on technical considerations for AM devices describing how the whole 
process (from the design to the post-processing control) has to comply with specific criteria in order 
to receive the approval for clinical uses.[292] Ideally, after receiving the FDA certification, each 
hospital could possess a dedicated center able to collect the requests from all the departments to 
manufacture bio-constructs for the specific requirements of each patient, including its own cells. 
Additionally, it would help disseminating the advantages of such an approach, overcoming also any 
mistrust that is often boosted by unreferenced sources. 
In conclusion, despite the encouraging results achieved for both the hard/soft materials there are still 
several questions that need to be answered in order to properly tune the HA-based materials for each 
specific purpose and fabrication process. A better understanding on the sensitivity of the final 
outcome for each involved parameter, of the material and of the AM process, will definitely represent 
the key to fabricate improved customized devices for replacing/regenerating cartilaginous/bone 
tissues with strong implications also on other classes of biocomposites processed via AM in view of 
other applications in the biomedical field. 
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